Skip to main content

Table 3 Patients characteristics

From: A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass

 

Serum (training cohort)

Serum (validation cohort)

Tissue

 

Cancer

LMP

Benign

Cancer

LMP

Benign

Cancer

LMP

Benign

Patients

53

18

57

16

5

21

40

20

24

Age (years)

59.2 (11.4)

53.5 (10.3)

56.6 (12.4)

58.0 (14.8)

43.3 (8.0)

54.0 (14.5)

55.8 (11.7)

50.7 (10.3)

53.4 (15.3)

BMI

26.1 (5.4)

28.7 (8.0)

26.9 (6.0)

26.5 (4.5)

27.4 (5.8)

26.6 (4.1)

26.1 (4.5)

28.8 (8.0)

26.7 (5.0)

Premenopausal

10

6

22

5

5

11

13

10

9

Postmenopausal

43

12

35

11

 

10

27

10

15

Sample age (years)

2.5 (0.9)

2.3 (0.5)

2.5 (0.6)

0.7 (0.4)

0.6 (0.2)

1.7 (1.2)

2.5 (1.2)

2.5 (1.0)

2.7 (0.9)

CA125 kU/L

2451

63

42

5078

131

67

4117

89

26

(range)

(7–14100)

(6–396)

(1–164)

(111–67448)

(56–284)

(2–312)

(7–67448)

(6–396)

(5–164)

Histological type

         

Serous

38

13

 

13

3

 

32

6

 

Mucinous

5

5

 

1

2

 

2

14

 

Endometrioid

3

  

1

  

2

  

Undifferentiated

5

  

1

  

3

  

Clearcell

2

     

1

  

Grade

         

1

2

     

2

  

2

12

  

3

  

9

  

3

39

  

12

  

29

  

NA

   

1

     

Figo Stage

         

I

6

     

6

  

II

3

     

1

  

III

36

  

13

  

27

  

IV

8

  

3

  

6

  
  1. Clinical and pathological characteristics of the three separate patient groups: cancer, low malignant potential (LMP) and benign tumor. The characteristics are given for the serum training, serum validation and tissue experiments. Age, body mass index (BMI) and sample age are given as a mean value with their standard deviation. In one patient differentiation grade was not available (NA).
Back to article page

Proteome Science

ISSN: 1477-5956